In July 2013, afatinib was approved for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations by the US Food and Drug Administration (104). This evidence concerns the gene EGFR and non-small cell lung carcinoma.